Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Spondylitis Trial of Apremilast for Better Rheumatic Therapy
Ankylosing Spondylitis
Primary: Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline — -0.77; -1.59 units on a scale — p=0.139
Phase 3 N=192 Study of Adalimumab in Patients With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response — 14; 33 participants — p=<0.001
N/A N=147 Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid Arthritis · Bone Resorption · Ankylosing Spondylitis
Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
Phase 4 N=24 Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy
Spondylarthropathies, Enthesitis
Primary: Normalized Net Incremental Area Under the Curve (AUC) for Patient Global Assessment of Disease Activity (PGA) Between Randomization and Week 12 — -28.54; -11.07 mm…
Phase 3 N=225 Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving Ankylosing Spondylitis (ASAS) 40 Response at Week 12 — 32.38; 15.74 Percentage of participants — p=0.0062
Phase 3 N=158 Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
Ankylosing Spondylitis · Axial Spondyloarthritis
Primary: Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28 — 65; 18; 40; 33 Participants
Phase 4 N=82 Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) Between Randomization and Week 12 — -19.79…
Phase 3 N=165 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
Peripheral Spondyloarthritis
Primary: Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12 — 39.3; 19.8; 60.7; 80.2 percentage of participants — p=0.006
Phase 4 N=566 Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) — 287; 99 participants — p=<0.001
N/A N=763 Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel
Spondyloarthrosis
Primary: Percentage of Participants With 7 Years Adherence to Etanercept — 60.6 Percentage of participants
Phase 4 N=90 A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Change From Baseline in Non Steroidal Anti Inflammatory Drug (NSAID) Assessment of the SpondyloArthritis International Society (ASAS) Score at Week 8. — -63.90; -36.63…
Phase 3 N=82 Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12 — 18; 12; 20; 32…
Phase 3 N=64 Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
Axial Spondyloarthritis
Primary: Proportion of Patients Achieving Sustained Clinical Remission — 34 Participants
N/A N=80 Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.
Ankylosing Spondylitis
Primary: Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Baseline — 30.18; 49.09; 53.06; 63.29 Percentage of impairment
N/A N=1,685 Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving Partial Remission at Week 26 — 19.0 percentage of participants
Phase 3 N=490 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Ankylosing Spondyloarthritis
Primary: Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16 — 36.6; 35.0; 32.5 Percentage of…
N/A N=152 Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Ankylosing Spondylitis
Primary: Percentage of Participants With Unchanged First Line Anti-TNF Treatment Up to Month 18 — 85.42 percentage of participants
Phase 3 N=204 Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
Psoriatic Arthritis · Axial Spondyloarthritis · Enthesitis
Primary: Number (%) of Patients With Resolution of Achilles Tendon Enthesitis — 43; 32 Participants — p=0.136
N/A N=89 Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving BASDAI 40 Response at Week 24 — 83.6 Percentage of participants
N/A N=403 Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ankylosing Spondylitis
Primary: Number of Participants With Adverse Drug Reactions — 101; 15 Participants
Phase 3 N=356 A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Assessment in Ankylosing Spondylitis 20 Responders at Week 14 — 17; 82; 84; 166 Participants — p=<0.001
Phase 4 N=108 Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20. — 34; 37 patients — p=0.6031
N/A N=259 MRE as a Screening Tool for axSpA in IBD
Axial Spondyloarthritis · Crohn Disease
Primary: The Sensitivity and Specificity of MRE as a Screening Tool for Axial Spondyloarthritis in Crohn's Disease — 0.88; 0.50; 0.78 Probability
Phase 3 N=303 A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response — 19.0; 35.4; 40.2 percentage of participants — p=0.009
Phase 3 N=317 Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Axial Spondyloarthritis · Nonradiographic Axial Spondyloarthritis · Nr-axSpA
Primary: Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) Response Criteria Response at Week 52 — 7.0; 47.2 percentage of…
Phase 3 N=208 A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16…
Phase 3 N=498 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
Axial Psoratic Arthritis
Primary: Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12 — 66.3; 62.9; 31.2 percentage of participants…
N/A N=132 Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants With a Clinical Response — 90.9; 9.1 percentage of participants